| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
3-O-Ethyl-L-ascorbic acid targets tyrosinase, the key enzyme in melanin biosynthesis. It is a cosmetic tyrosinase inhibitor that inhibits the formation of melanin. By inhibiting tyrosinase, the compound reduces melanin production, leading to skin whitening and lightening of hyperpigmented areas. It also targets collagen synthesis pathways, promoting skin repair and elasticity.
|
|---|---|
| ln Vitro |
3-O-Ethyl-L-ascorbic acid demonstrates potent in vitro tyrosinase inhibitory activity. It inhibits melanin formation and restores melanin to a colorless state. The compound has strong antibacterial and anti-inflammatory effects. It effectively removes freckles, whitens skin, improves dull skin, and endorses skin elasticity by promoting collagen synthesis and repairing skin cell activity.
|
| ln Vivo |
In vivo activity data for 3-O-Ethyl-L-ascorbic acid are not extensively documented. Its topical application in cosmetic formulations suggests that it is effective in vivo for skin whitening and improving skin condition. It enters the dermis and directly participates in collagen synthesis. Further in vivo studies are needed to fully characterize its efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
The in vitro enzyme assay for 3-O-Ethyl-L-ascorbic acid involves measuring its inhibition of tyrosinase activity. Mushroom tyrosinase is commonly used as a model enzyme. The assay typically uses L-DOPA as a substrate, and the formation of dopachrome is monitored spectrophotometrically at 475 nm. 3-O-Ethyl-L-ascorbic acid is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for 3-O-Ethyl-L-ascorbic acid typically use B16 melanoma cells or human melanocytes to assess its effects on melanogenesis. Cells are treated with the compound at various concentrations. Melanin content is measured spectrophotometrically. Tyrosinase activity is assessed by measuring the oxidation of L-DOPA in cell lysates. Collagen synthesis can be assessed in fibroblasts by measuring collagen production.
|
| Animal Protocol |
In vivo studies for 3-O-Ethyl-L-ascorbic acid are typically conducted in human subjects as part of cosmetic efficacy studies. The compound is applied topically in formulations. Skin lightening, reduction in pigmentation, and improvement in skin elasticity and hydration are assessed using clinical scoring, colorimetry, and biophysical measurements.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3-O-Ethyl-L-ascorbic acid are characterized by its stability and skin penetration. As a lipophilic derivative of vitamin C, it has better skin permeability than L-ascorbic acid. It enters the dermis and is available for collagen synthesis. Its metabolic fate and systemic absorption are not extensively documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-O-Ethyl-L-ascorbic acid are limited. As a cosmetic ingredient, it is generally considered safe for topical use. It has antibacterial and anti-inflammatory effects. Standard safety assessments for cosmetic ingredients, including skin irritation and sensitization tests, have likely been performed. Further toxicological studies would be required for systemic use.
|
| References |
|
| Additional Infomation |
3-O-ethyl ascorbic acid is a butenolactone.
See also: ... View more ... 3-O-Ethyl-L-ascorbic acid (Vitamin C ethyl ether) is a stable, lipophilic vitamin C derivative used in cosmetics for skin whitening, antioxidant protection, and collagen synthesis. It inhibits tyrosinase activity and melanin formation. The compound has antibacterial and anti-inflammatory effects. No clinical trials or regulatory approvals have been reported for this compound as a drug. |
| Molecular Formula |
C8H12O6
|
|---|---|
| Molecular Weight |
204.18
|
| Exact Mass |
204.063
|
| CAS # |
86404-04-8
|
| PubChem CID |
150736
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
551.5±50.0 °C at 760 mmHg
|
| Melting Point |
112.0 to 116.0 °C
|
| Flash Point |
228.5±23.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
259
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCOC1=C(C(=O)O[C@@H]1[C@H](CO)O)O
|
| InChi Key |
ZGSCRDSBTNQPMS-UJURSFKZSA-N
|
| InChi Code |
InChI=1S/C8H12O6/c1-2-13-7-5(11)8(12)14-6(7)4(10)3-9/h4,6,9-11H,2-3H2,1H3/t4-,6+/m0/s1
|
| Chemical Name |
(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-ethoxy-4-hydroxy-2H-furan-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (489.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (489.76 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8976 mL | 24.4882 mL | 48.9764 mL | |
| 5 mM | 0.9795 mL | 4.8976 mL | 9.7953 mL | |
| 10 mM | 0.4898 mL | 2.4488 mL | 4.8976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
